JAK1 and COVID-19: Thus, several studies have proposed that the JAK/STAT signaling inhibition may be a valuable preventive or therapeutic option for COVID-CS.126,300–305 The clinical efficacy of various JAK inhibitors (JAKinibs) such as tofacitinib targeting JAK1 and JAK3306,307 as well as baricitinib and ruxolitinib, both targeting JAK1 and JAK2,308–310 are currently under investigation in clinical trials in the context of COVID-19.